Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0M7KD
|
||||
| Former ID |
DNC013800
|
||||
| Drug Name |
Cyclobutylcarbamic Acid Biphenyl-3-yl Ester
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H17NO2
|
||||
| Canonical SMILES |
C1CC(C1)NC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
|
||||
| InChI |
1S/C17H17NO2/c19-17(18-15-9-5-10-15)20-16-11-4-8-14(12-16)13-6-2-1-3-7-13/h1-4,6-8,11-12,15H,5,9-10H2,(H,18,19)
|
||||
| InChIKey |
CACLVJBQOQELCV-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Fatty-acid amide hydrolase | Target Info | Inhibitor | [1] | |
| BioCyc Pathway | Anandamide degradation | ||||
| KEGG Pathway | Retrograde endocannabinoid signaling | ||||
| PANTHER Pathway | Anandamide degradation | ||||
| References | |||||
| REF 1 | J Med Chem. 2008 Jun 26;51(12):3487-98. Epub 2008 May 29.Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.